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Summary.-The results are reported of a small clinical trial carried out to assess the
potential value of the hypoxic cell radiosensitizer misonidazole in the radiation
treatment of Grade 3 and 4 supratentorial astrocytomas. A total of 55 patients were
randomly allocated to one of 3 treatment groups. No significant differences were seen
between the median survivals of patients in the 2 control radiation groups and that of
the third group in which oral misonidazole at a dose of 3 g/m2 preceded each of
4 weekly radiation doses. Possible reasons why no improvement was seen are dis-
cussed in detail.
THE SURGICAL TREATMENT of Grade 3
and 4 supratentorial astrocytomas re-
mains unsatisfactory, despite the many
attempts to improve results by combined-
modality treatments with radiotherapy
and chemotherapy. The median survival
for patients treated by surgery alone is
less than 6 months, and fewer than 500
survive at 3 years (Walker & Strike, 1979;
Bloom, 1975). Postoperative radiotherapy
marginally improves the results (Roth &
Elvidge, 1960; Taveras et al., 1962;
Hitchcock & Sato, 1964; Jelsma & Bucy,
1967; Walker & Strike, 1979). The addi-
tion of chemotherapy with a nitrosourea
to the postoperative radiotherapy im-
proves survival further (BCNU Walker
& Strike, 1979; Brisman et al., 1976;
CCNU Hildebrand, 1979) though this is
not confirmed in a smaller series with
CCNU (Garrett et al., 1978). The use of
chemotherapy alone has remained dis-
appointing (Hildebrand, 1979; Walker &
Strike, 1979).
The failure to control what is essentially
a localized disease by radiotherapy is dis-
appointing, and probably relates to the
radiosensitivity of normal brain tissue,
which does not permit curative radiation
doses without unacceptable morbidity.
Malignant gliomas are known to contain
many necrotic areas, and it seems possible
that resistance to radiation may be the
result of hypoxic cells. Chemical radio-
sensitizers of hypoxic cells have been
described in an experimental setting
(Fowler et al., 1976) and in a small study of
the radiation treatment of cerebral astro-
cytomas (Urtasun et al., 1976) metronid-
azole appeared to improve the results of
radiotherapy. Numerous studies have been
started with another radiosensitizer,
misonidazole (1-(2-nitro-1-imidazole)-3-
methoxy-2-propanol, Ro-07-0582, MISO)
and these are currently in progress.
This report presents the results ofasmall
randomized study comparing the post-
operative effects of 2 different radiation
schedules without MISO and one of these
schedules together with the drug. Pre-
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TABLE I. Details of %
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Total patients/group
Males
Females
Age
Mean (years)
Range
MIean performance status*
Range
Tumour site
Frontal
Parietal
Temporal
Otlier
Surgery
Biopsy only
Tumour resection
Histology
Grade 3
Grade 4
3
* Performance status scoI
1-normal activity
2 Light work
3 Can care for self
4 Limited self-care,
or chair
5 Fully disabled anc
design ofthis study sample was taken. They Awere also stratified
3) and early results according to histological grade, according to
been published else- the classification ofKernohan & Sayre (1952).
Details of patients are presented in Table I.
The performance status on a 5-grade
Medical Research Council scale was recorded ovDs at the start of treatment and at follow-up
Mnts of either sex and (Table II).
and 75, with a supra- Treatment.-After stratification, patients
iom histological con- were allocated on the basis of random num-
of Grade 3 or 4 astro- bers to one of the following treatment
ned, were eligible for schedules:
istory of other malig- Group A: 56-56 Gy (5656 rad) in 28 equal
:ely to affect survival, fractions of 2-02 Gy/fraction over 51 wA-eeks
ion, rendered patients (1702 ret).
-h gross neurological Group B: 43 52 Gy (4352 rad) in 12 unequal
;ciousness were also fractions over 4 weeks. These were delivered
provided that it was thrice weekly with 2-94 Gy on Mondays and
ier major defects, did Wednesdays and 5 Gy on Fridays.
Group C: The same radiation schedules as
s were randomized to in Group B with the addition ofMISO 3 g/m2
roups, after stratifica- given by mouth after a light breakfast 4-5 h
irther criteria. These before the 5 Gy dose on Fridays. Thus a
ents from whom most cumulative dose of 12 g/m2 of MISO w%as
resected and for those given in 4 weekly doses.
rate or small biopsy The radiation dose in Group A was selected
on the basis of our previous experience. The
schedules in Groups B and C were also calcu-
vatients on entry into lated to be the equivalent of 1702 ret (the
ly equivalent single dose in rads), but were
Group selected to provide what we believed to be
-> ~ \optimum radiosensitization by MISO. Group
A B C B was therefore necessary as an additional
20 18 17 control to that provided by Group A.
11 12 11 Megavoltage radiation either from cobalt-
9 6 6 60 or a 6MeV linear accelerator was delivered
54.9 49.6 50 4 through parallel opposed fields. The volume
,2-66 27-75 18-66 was at least two thirds of the supratentorial
3.4 3.3 3 0 brain, with the anterio-posterior borders
2-5 1-5 I-5 determined by the position of the gross
tumour. However, no attempt was made to
6 8 7 restrict the treatment volume to the defined
5 3 6 gross tumour, in view of its propensity to
63 3 3 spread widely through the brain.
Patients were given dexamethasone (2 mg
5 6 ,5 t.d.s. during the radiotherapy) and the
15 12 12 steroid dosage was maintained afterwards as
indicated clinically. All patients received
13 14 13 the designated protocol treatment without
7 4 4 significant deviation.
ring system: Anticonvulsant therapy waAs given to a
total of 26 of the 55 patients as follows:
Group A-phenytoin 7; Group B-phenytoin
partially confined to bed 4, phenobarbitone 3; Group C-phenytoin 9, phenobarbitone 2, both drugs 1. They were
A confined to chair or bed maintained on these drugs at appropriate
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dosage from some time before radiotherapy
was begun. No other anti-cancer drugs were
givenduringtheprimarytreatment. However,
CCNU (13 patients) and procarbazine (1
patient) were used on relapse not less than 3
months after completion of the protocol
therapy. The decision to give chemotherapy
was made on the basis ofthe clinical condition
ofthe patients, and without knowledge ofthe
treatment they had previously received.
Fewer patients received this secondtreatment
in Group C (3 patients) than in Group A (6
patients) and Group B (5 patients).
Plasma misonidazole estimation.-Full de-
tails of the method by reverse-phase high-
performance chromotography have been re-
ported elsewhere (Workman et al., 1978).
Plasma was prepared by centrifugation of
heparinized blood at 4°C and samples stored
at -20°C until analysed. Blood samples were
always taken 4 h after drug ingestion, just
before the radiation treatment. Additional
samples were also taken at intervals before
and after.
100
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RESULTS
Case accrual was stopped at the end of
1978 because new patients were then
entered into a multicentre study co-
ordinated by the Medical Research Coun-
cil. All patients have been seen at regular
intervals until death. No patient was lost
to follow-up. The analysis presented in
the Fig. and Table II represents a com-
plete follow-up, as all patients have now
died. It can be seen that no difference is
apparent in the survival of patients
treated by the three regimens. The median
survivals for Group A are 251 days, for
Group B, 220 days and for Group C, 270
days. The survival rate at 1 year of all
groups of patients combined was 14/55
(25%).
There was some improvement in the
performance status of patients after treat-
ment, as seen in Table II, but only a few
200
DAYS
FIGURE.I Survival of patients allocated to the 3 treatment groups. A Group A; 0 Group B; A Group C.
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TABLE II.-Response of patients to treat- but none were given additional anti-
ment tumour chemotherapy. Their patients
Group were randomized into 2 groups. One group
A of 15 patients received radiation alone
A B C whilst the other with 16 patients received
Overall median survival
(days) 251 220 270 radiation together with i.V. high-dose
Grade 3 318 219 275 metronidazole (150 mg/kg). An increase
Grade 4 92 224 270 in the median survival from 15 to 26
Performance status weeks was seen. This difference was judged
Initial mean 3-4 3-3 3 0 statistically significant at the conventional
Best post-treatment
mean 2-2 1-8 2-2 level, but wth such small numbers of
patients the true level of improvement
showed major improvement. Numbers of achievable by metronidazole could not be
patients were too small to test for signifi- accurately determined, and could con-
cant differences between the groups. ceivably be quite small. In contrast, our
Plasma MISO concentrations were study has shown no real improvement in
monitored at the time of radiotherapy, survival as a result of treatment with
i.e. about 4 h after each dose in 16/17 MISO.
patients allocated to receive the drug. The The poor result of the control group in
mean plasma concentration was 92+32 the Canadian study may be ascribed to
/g/ml, with an overall range of 49-189jug/ the low radiation dose (1288 ret) as com-
ml. There was some variation in the con- pared with those more conventionally
centrations achieved after individual used. Thus in a series of protocols carried
doses in the same patient. The maximum out by the N.C.I. Brain Tumour Study
range in one patient over the 4 doses ofthe Group (Walker et al., 1979) there was a
drug was 49-94,ug/ml. The mean plasma progressive increase in median survival
MISO half-life (t1) was 8*6 h + 0*62. with increasing radiation dose over the
Nopatients developedsignificantperiph- range 4500-6000 Gy (daily fractions for
eral neuropathy. Assessment of central- 5 days per week over 41-6 weeks). At the
nervous-system toxicity was more diffi- highest dose, the median survival time
cult, because of the nature of the disease was 42 weeks, similar to that seen in our
being treated. We were not aware of any study but much longer than that in the
such damage in our patients. Canadian metronidazole group. Even
longer median survival times have been
DISCUSSION reported in a non-randomized study on patients; with Grade 3 tumours of 91
This study was based on the hypothesis weeks and of 42 weeks for Grade 4
that resistant hypoxic tumour cells con- tumours (Salazar et al., 1979). It seems
tribute to the poor results ofthe combined likely therefore that metronidazole im-
surgical and radiotherapeutic manage- proved the poor results due to the low
ment ofhigh-grade cerebral astrocytomas. radiation dose in the study reported by
The results are disappointing when com- Urtasun et al. Indeed, in a new study with
pared with those presented by Urtasun more conventional radiation dosage,
and his colleagues (1976) using metronid- metronidazole has not shown its previous
azole. In that Canadian study, 31 assess- effectiveness (Urtasun, personal communi-
able patients were treated to a total cation, 1980).
tumour dose of 30 Gy by 9 fractions (3 In our study there are several possible
times per week) in an overall time of 18 reasons why no improvement in survival
days, with radiation fields similar to that was seen after treatment with radiation
used in our study. All received dexa- and MISO.
methasone during and after radiotherapy, A relatively small number of patients
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were entered into the study for the reason
already stated. With these numbers there
was only a small chance of detecting an
increase in median survival of 15 weeks
(i.e. from 30 to 45 weeks) and no better
than an even chance of detecting an in-
crease of25 weeks. Such a study could only
be reasonably sure ofdetecting an increase
in median survival time of 60 weeks
minimum, so it is not particularly sur-
prising that no difference was found.
A second possible reason is that radio-
biological hypoxia may not be present in
a significant amount in cerebral gliomas.
Clinical studies using alternative tech-
niques to overcome the potential problem
of hypoxia in gliomas, such as hyperbaric
02 (Chang, 1977) and fast-neutron therapy
Laramore et al., 1978; Batterman, 1980;
Catterall et al., 1980), have not demon-
strated any improvement in survival over
comparable patients treated by photons.
There was, however, some reported im-
provement of local tumour control at
postmortem examination. The data from
the first metronidazole study (Urtasun et
al., 1976) might also suggest that hypoxia
was a problem, in that improvement due
to the drug was noted, with the suboptimal
radiation schedule.
A further reason for failure to demon-
strate differences may relate to the treat-
ment schedules which were adopted. There
is no general agreement as to an optimum
radiation dose and fractionation schedules
for the treatment of gliomas. Convention-
ally, daily fractions of 1P8-2-0 Gy are
given, to total doses of 45-65 Gy (Bloom,
1975; Walker et al., 1979; Salazar et al.,
1979). The tissue volume treated also
varies from that ofthe whole brain with or
without a boost to the tumour, to smaller
more restricted volumes throughout the
entire treatment. We opted to use as our
control regimen, a schedule with which we
had had much previous experience and
which had produced a median survival of
about 9 months. This was comparable to
that achieved in most other reports, as
discussed previously. At the time the
study was designed, we believed that
optimal radiosensitization by MISO would
be obtained with the use of a few large
drug doses in order to obtain high serum
and therefore tumour concentrations.
Because of its dose-limiting neurotoxicity
(Dische et al., 1978) we restricted the total
cumulative drug dose to 12 g/m2; and
therefore elected that 4 treatment frac-
tions be given of 3 g/m2 each. We also
expected that it would be better to use
large radiation fractions with these drug
doses in order to achieve maximum
tumour-cell kill. A preliminary pilot study
demonstrated that 5Gy fractions were well
tolerated. We therefore decided to give
smaller radiation doses twice a week and
reserve the larger dose with drug on
Fridays to permit recovery of the patient
from any excess cerebral oedema over the
weekend. There were no adequate guide-
lines for a dose comparison between such
a schedule and the conventional 5-day-
week regime, so it was therefore necessary
to have an additional control of the un-
conventional regimen without sensitizers.
The total doses were calculated to be
equivalent in terms of NSD, as 1702 ret.
(Orton & Ellis, 1973). However, such
calculations are probably only valid for
skin and s.c. tissue from which the
original NSD data were obtained. There
is now evidence that the NSD formula
(that is, with a fractional exponent of
0-24, and a time exponent of 0.11) may
not apply in the calculation of central-
nervous-system tolerance, at least for the
rodent spinal cord (Van der Kogel, 1979;
Hornsey & White, 1980). Only a very
large clinical study would detect minor
differences, but it is reassuring that
survival was not significantly different
between the 2 control radiation groups.
Our initial premise that it would be best
to administer the MISO in a few large
fractions may also have been incorrect. It
has subsequently been reported, on the
basis of computer modelling, that multiple
small doses of the sensitizer with con-
ventional daily radiation fractions or
sensitization at the beginning of a treat-
ment course might be most advantageous
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(Denekamp et al., 1980). However, the
validity of this model still remains to be
proved. An additional reason for the result
might arise if MISO sensitized normal
brain tissue to radiation. Although it is
usually believed only to sensitize hypoxic
cells and tissues (Fowler et al., 1976), there
remains the possibility that there is a
degree of hypoxia in the central nervous
system. Thus MISO sensitization has been
reported in the spinal cord of the rat
(Yuhas, 1979), but anaesthesia may have
contributed to this effect. Increased radi-
ation reaction in the normal oropharyn-
geal mucosa of unaesthesized patients has
also been documented (Arcangeli et al.,
1980). Once again hard data are still
lacking on this topic.
We have been concerned as to the
optimal time at which radiation treatment
should be given after oral MISO. We
selected 4-5 h on the basis of data from
tumour biopsies at other sites (Gray et al.,
1976; Wiltshire et al., 1978; Ash et al.,
1979). We have subsequently investigated
this problem by estimating drug concen-
tration in brain-tumour samples in a series
ofpatients biopsied at different times after
drug administration. Tumour concentra-
tions comparable to those seen at other
tumour sites are seen, with similar time
course. This work will be reported in detail
elsewhere. Unless the mean concentrations
in tumour do not indicate adequate drug
penetration to the smaller proportion of
hypoxic cells, it seems unlikely that the
drug concentration is inadequate to
achieve radiosensitization.
Brief comment should be made on the
absence of MISO-induced neurotoxicity
from this study. We believe that this is the
result of two separate phenomena. We
have shown that anticonvulsant therapy
with phenytoin (Workman et al., 1980)
and phenobarbitone (unpublished) reduce
the plasma half-life of MISO because
of hepatic microsomal-enzyme induction.
The t- of 8-6 h + 0-62 observed in this
study, compared to 11*5 h + 3 8 in our
experience of patients without brain
tumours, suggests that increased drug
metabolism may be reducing the periph-
eral-nerve exposure to MISO. This has
been discussed in more detail elsewhere
(Bleehen, 1980). In addition, all our
patients were receiving dexamethasone,
and this drug has been reported to reduce
the incidence of MISO neurotoxicity
(Wasserman et al., 1980).
In conclusion we can therefore only
speculate as to the reasons for the outcome
of the present study. The combined sur-
vival rate of 25% at 1 year and ultimate
death of all patients leaves no room for
complacency. There was also only a small
improvement in the performance status of
the patients so treated, though a few were
able to return to a relatively normal life.
Much work is still required to improve on
these results, and the many on-going
studies, including a large MRC trial, with a
variety of fractionation schedules, may
well resolve this issue.
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and Mrs J. Donaldson for the estimations of misonid-
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Welwyn, Limited) for the generous supply of
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